Case Study

Lengthy Cancer Drug Study Using Dozens Of Sites Yields Positive Results

Patient Engagement

A three-nation study of a treatment for recurring glioblastoma showed the therapy more than five times as effective as the typical protocol, an unexpectedly large advance in fighting these aggressive brain tumors. But it was a long road, and the drug’s efficacy was a big factor in extending the trial to five years – nearly twice its expected duration.

Yes, recruiting was time consuming – it took 21 months to find the 84 patients who were ultimately randomized and treated in this Phase II evaluation of an antibody-like human fusion protein. And it took extra effort to ensure that devices used across more than two dozen study sites were accurately calibrated.

VIEW THE CASE STUDY!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Clinical Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: